Copyright
©The Author(s) 2020.
World J Gastrointest Oncol. Feb 15, 2020; 12(2): 182-194
Published online Feb 15, 2020. doi: 10.4251/wjgo.v12.i2.182
Published online Feb 15, 2020. doi: 10.4251/wjgo.v12.i2.182
Table 2 Treatment data and efficacy of FOLFIRINOX and gemcitabine plus nab-paclitaxel, n (%)
| FOLFIRINOX (n = 86) | Gem + nabPTX (n = 81) | P value | |
| Duration of chemotherapy | |||
| Cycles | 8 (2-24) | 5 (2-16) | |
| Duration, days | 138 (19-551) | 154 (32-554) | 0.249 |
| Accumulation dose, mg/m2 | |||
| Gemcitabine | 14000 (4000-40000) | ||
| Nab-paclitaxel | 1562.5 (375-4875) | ||
| 5-Fluorouracil | 16800 (5600-53200) | ||
| Oxaliplatin | 510 (170-1445) | ||
| Irinotecan | 1080 (360-3060) | ||
| Relative dose intensity, % | |||
| Gemcitabine | 93.3 (54.3-100) | ||
| Nab-paclitaxel | 86.2 (22.7-100) | ||
| 5-Fluorouracil | 80.0 (52.5-100.0) | ||
| Oxaliplatin | 75.0 (52.5-100.0) | ||
| Irinotecan | 75.0 (52.5-100.0) | ||
| Best response of chemotherapy | 0.067 | ||
| Complete response | 0 (0) | 0 (0) | |
| Partial response | 29 (33.7) | 38 (46.9) | |
| Stable disease | 31 (36.0) | 30 (37.0) | |
| Progression of disease | 26 (30.2) | 13 (16.0) | |
| Response rates | |||
| Objective response rate | 29 (33.7) | 38 (46.9) | 0.082 |
| Disease control rate | 60 (69.8) | 68 (84.0) | 0.03 |
- Citation: Cho IR, Kang H, Jo JH, Lee HS, Chung MJ, Park JY, Park SW, Song SY, An C, Park MS, Bang S. FOLFIRINOX vs gemcitabine/nab-paclitaxel for treatment of metastatic pancreatic cancer: Single-center cohort study. World J Gastrointest Oncol 2020; 12(2): 182-194
- URL: https://www.wjgnet.com/1948-5204/full/v12/i2/182.htm
- DOI: https://dx.doi.org/10.4251/wjgo.v12.i2.182